Reageer voor: 18 januari 2018 / Soort dienstverband: Bepaalde tijd / Aantal uren: 36 uur per week / Vakgebied: AMC Medical Research (AMR)
As a postdoc, you will work on a project aiming to identify novel molecular targets and drugs for precision therapy of diffuse large B cell lymphoma, the most prevalent type of non-Hodgkin lymphoma. The position involves cross-disciplinary collaborations within the AMC.
The project is supported by a grant to Dr. M. Spaargaren (dept. of Pathology, AMC) of Lymph & Co (www.lymph-co.com), a foundation dedicated to lymphoma research. The aim of the project is to identify novel targets and drugs for (personalized) precision treatment of diffuse large B cell lymphoma, and involves a.o. loss-of-adhesion and synthetic lethality screens with kinome-centered CRISPR- and shRNA-libraries, various molecular and cell biological techniques, and translational xenotransplant mouse models. Considering microenvironment-dependence as their Achilles’ heel, the focus is on the identification of kinases involved in the regulation of the critical interaction of the malignant cells with the lymphoid organ microenvironment, including B-cell antigen receptor-, chemokine- and growth factor-controlled regulation of integrin-mediated adhesion. This project is expected to identify novel therapeutic targets and drugs, and to deliver rational combination-therapies in order to prevent therapy-resistance, leading to improved treatment strategies for lymphoma. The project is carried out in a research team led by Dr. M. Spaargaren, in close collaboration with Prof. S.T. Pals (dept. of Pathology, AMC) and Prof. M.J. Kersten (dept. of Hematology, AMC), and is embedded in the research program of the Lymphoma and Myeloma Center Amsterdam (LYMMCARE; www.lymmcare.nl) and in the AMC-VUmc oncological alliance institute Cancer Center Amsterdam (CCA; www.amsterdamresearch.org/web/cancer-center-amsterdam/home-2.htm).
Pathology: The hemato-oncological research of the Department of Pathology is embedded in the Lymphoma and Myeloma Center Amsterdam (LYMMCARE) and in the AMC-VUmc oncological alliance institute Cancer Center Amsterdam (CCA). The major aims of the research teams led by Dr M. Spaargaren and Prof. S.T. Pals are (1) to identify and molecularly dissect the signaling pathways involved in differentiation and function of B lymphocytes and in the pathogenesis of B-cell malignancies, and (2) to explore and exploit microenvironment-dependence as the Achilles’ heel of B-cell malignancies, focussing on diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, multiple myeloma and Waldenström’s macroglobulinaemia. Our mission is to exploit this knowledge to improve the diagnosis and treatment of non-Hodgkin lymphoma and multiple myeloma. Dr. M. Spaargaren is dean of the Oncology graduate school Amsterdam (OOA) of the NKI, VUmc and AMC, theme-leader of the CCA theme on Target Discovery and Preclinical Therapy Development, and chair of the Society for Cancer Biology of the Dutch Cancer Society (KWF).
You are a highly motivated and ambitious postdoc with a PhD degree in Biomedical Sciences or equivalent and have gained ample experience with molecular and cell biology research, preferably in the field of oncology or immunology. Preferentially, you possess laboratory skills in cell culturing, PCR, DNA-techniques, cell transfections or viral transduction, and flow cytometry. Additional experience in bioinformatics, statistics and animal studies (art. 9) is desirable. This project involves close collaborations with other (clinical) departments such as Hematology; therefore, you should be able to work in a multi-disciplinary team.
We offer a challenging research project and excellent research facilities. The Postdoc will be appointed in a full-time position (36 hours/week) for a period of four years.
You will be employed by AMC Medical Research BV. Gross monthly salary will be in accordance with the Collective Labour Agreement for Dutch Universities. The gross monthly salary ranges from € 3.202,- to € 4.216,-. We offer a range of added fringe benefits, such as an annual bonus of 8.3 %, holiday allowance of 8%, collective discounted rates for a number of insurances, an attractive bicycle scheme and/or public transport allowance, and free parking.
For more information please contact: Dr. Marcel Spaargaren, email@example.com, +31205664936.